Jian Shi

Dr. Jian Shi


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
ZWZhishan Wu
Zhishan Wu
CWChao Wu
Chao Wu
JSJian Shi
Jian Shi
ZHZhihong Huang
Zhihong Huang
SLShan Lu
Shan Lu
JWJiarui Wu
Jiarui Wu
Compound Kushen injection (CKI) is a representative medication of Chinese herbal injection and is often used in the adjuvant treatment of nasopharyngeal carcinoma (NPC), but its antitumor mechanism is poorly understood. To preliminarily elucidate the effects and possible mechanisms of CKI on NPC. In this work, we explored the possible molecular mechanisms of CKI against NPC by using network pharmacology and molecular docking. In addition, proteomics was used to explore the localization and quantitative information of protein in NPC C666-1 cells after the intervention of CKI, and enrichment analysis was used to obtain the potential targets and pathways. Finally, the effect and the core targets of CKI in the intervention of NPC were explored in vitro experiments. Network pharmacology analysis identified three active components of CKI and 13 key targets. Molecular docking analysis showed that TNF, PTEN, CCND1, MAPK3, IL6, HIF1A, MYC had high affinity with corresponding components. Then the key pathway, cell cycle and the core targets MYC, CCND1, and P15 related to the key pathway were obtained. The results of in vitro experiments showed that CKI could inhibit the proliferation, migration, and invasion of NPC 5-8F cells and C666-1 cells, induce apoptosis of C666-1 cells, and arrest cell cycle G0/G1 phase. In addition, RT-qPCR and western blot showed that the expression of P15 was up-regulated and E2F4, E2F5, c-Myc, CCND1, and P107 was down-regulated in 5-8F cells and C666-1 cells intervened by CKI. The key pathway, cell cycle and the corresponding core targets MYC, CCND1, and P15 were obtained from network pharmacology, molecular docking, and proteomics. CKI could inhibit the proliferation, migration, and invasion of NPC cells, induce apoptosis of C666-1 cells. Especially CKI may arrest cell cycle G0/G1 phase through regulating targets MYC/P15/CCND1 of cell cycle pathway.

15 May 2018 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
DJDa Jiang
Da Jiang
JSJian Shi
Jian Shi
MYMeng Yuan
Meng Yuan
XDXiaoyang Duan
Xiaoyang Duan
LLLihua Li
Lihua Li
QLQian Li
Qian Li
Elevated bilirubin has been associated with protection of cardiovascular and kidney systems, whereas decreased bilirubin may predispose respiratory diseases. However, whether serum bilirubin levels are associated with lung cancer remains unclear. Here, clinical and pathologic data of a cohort of 363 lung cancer patients along with 363 age-and gender-matched healthy subjects were collected. The association of serum bilirubin levels with lung cancer was analyzed. The levels of serum bilirubin were significantly lower in lung cancer patients. The aspartate transaminase and alkaline phosphatase levels were significantly higher in lung cancer. Multi-classification logistics regression analysis revealed low total bilirubin level [OR (95%CI), 1.12 (1.02-1.23)], aspartate transaminase [OR (95%CI), 1.12 (1.02-1.23)], and alanine transaminase [OR (95%CI), 1.12 (1.02-1.23)] were risk factors in lung cancer. Serum bilirubin levels were significantly changed among small cell lung cancer (SCLC), lung adenocarcinoma (LAC) and lung squamous cell carcinoma (LSC). Total bilirubin level, smoke history and heart disease were risk factors for subtypes. Compared with LSC, patients with smoke history had significant higher risk in LAC [OR (95% Confidence Interval, CI), 4.49 (1.70, 11.96)]. Compared with LSC, patients with smoke history [OR (95%CI), 4.49 (1.70, 11.96)] and heart disease [OR (95%CI), 4.49 (1.70, 11.96)] had significant higher risk in SCLC. Compared with SCLC, patients with low total bilirubin [OR (95%CI), 1.12 (1.02-1.23)] and heart disease [OR (95%CI), 3.52 (1.01-12.23)] had significant higher risk in LAC. Taken together, these results suggested low serum bilirubin levels are tightly associated with lung cancer, especially with LAC. Serum bilirubin levels might serve as a predictor for lung cancer patients clinically.

19 May 2023 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
XDXiaoyang Duan
Xiaoyang Duan
HDHuazhen Du
Huazhen Du
MYMeng Yuan
Meng Yuan
LLLie Liu
Lie Liu
RLRongfeng Liu
Rongfeng Liu
JSJian Shi
Jian Shi
Esophageal carcinoma (ESCA) is one of the most common malignancies in the world, and has high morbidity and mortality rates. Necrosis and long noncoding RNAs (lncRNAs) are involved in the progression of ESCA; however, the specific mechanism has not been clarified. The aim of the present study was to investigate the role of necrosis‑related lncRNAs (nrlncRNAs) in patients with ESCA by bioinformatics analysis, and to establish a nrlncRNA model to predict ESCA immune infiltration and prognosis. To form synthetic matrices, ESCA transcriptome data and related information were obtained from The Cancer Genome Atlas. A nrlncRNA model was established by coexpression, univariate Cox (Uni‑Cox), and least absolute shrinkage and selection operator analyses. The predictive ability of this model was evaluated by Kaplan‑Meier, receiver operating characteristic (ROC) curve, Uni‑Cox, multivariate Cox regression, nomogram and calibration curve analyses. A model containing eight nrlncRNAs was generated. The areas under the ROC curves for 1‑, 3‑ and 5‑year overall survival were 0.746, 0.671 and 0.812, respectively. A high‑risk score according to this model could be used as an indicator for systemic therapy use, since the half‑maximum inhibitory concentration values varied significantly between the high‑risk and low‑risk groups. Based on the expression of eight prognosis‑related nrlncRNAs, the patients with ESCA were regrouped using the ‘ConsensusClusterPlus’ package to explore potential molecular subgroups responding to immunotherapy. The patients with ESCA were divided into three clusters based on the eight nrlncRNAs that constituted the risk model: The most low‑risk group patients were classified into cluster 1, and the high‑risk group patients were mainly concentrated in clusters 2 and 3. Survival analysis showed that Cluster 1 had a better survival than the other groups (P=0.016). This classification system could contribute to precision treatment. Furthermore, two nrlncRNAs (LINC02811 and LINC00299) were assessed in the esophageal epithelial cell line HET‑1A, and in the human esophageal cancer cell lines KYSE150 and TE1. There were significant differences in the expression levels of these lncRNAs between tumor and normal cells. In conclusion, the present study suggested that nrlncRNA models may predict the prognosis of patients with ESCA, and provide guidance for immunotherapy and chemotherapy decision making. Furthermore, the present study provided strategies to promote the development of individualized and precise treatment for patients with ESCA.

1 December 2014
Verified
Journal Article
Open access
XDXiaoyang Duan
Xiaoyang Duan
JSJian Shi
Jian Shi
近年来,在非小细胞肺癌(non-small cell lung cancer, NSCLC)靶向治疗中,尤其是伴有表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变的患者,EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)越来越多地进入到临床治疗,但EGFR-TKI耐药的产生不仅影响药物敏感性,甚至出现疾病进展,成为制约其疗效的主要瓶颈。微小RNA(microRNAs, miRNAs)是一种非编码蛋白的RNA,参与转录后水平基因的表达调控,最近研究发现,miRNAs参与了EGFR-TKIs耐药,影响肿瘤细胞对吉非替尼的敏感性。本文就NSCLC中miRNAs与EGFR-TKIs继发性耐药之间的相关性研究进展做简要的综述。

17 June 2024 in Thoracic Cancer
Verified
Journal Article
Open access
HYHuang Yajie
Huang Yajie
YZYaozhong Zhang
Yaozhong Zhang
XDXiaoyang Duan
Xiaoyang Duan
RHRan Hou
Ran Hou
QWQi Wang
Qi Wang
JSJian Shi
Jian Shi
Background: Improving immunotherapy efficacy for EGFR‐negative lung adenocarcinoma (LUAD) patients remains a critical challenge, and the therapeutic effect of immunotherapy is largely determined by the tumor microenvironment (TME). Tumor‐associated macrophages (TAMs) are the top‐ranked immune infiltrating cells in the TME, and M2‐TAMs exert potent roles in tumor promotion and chemotherapy resistance. An M2‐TAM‐based prognostic signature was constructed by integrative analysis of single‐cell RNA‐seq (scRNA‐seq) and bulk RNA‐seq data to reveal the immune landscape and select drugs in EGFR‐negative LUAD.Methods: M2‐TAM‐based biomarkers were obtained from the intersection of bulk RNA‐seq data and scRNA‐seq data. After consensus clustering of EGFR‐negative LUAD into different clusters based on M2‐TAM‐based genes, we compared the prognosis, clinical features, estimate scores, immune infiltration, and checkpoint genes among the clusters. Next, we combined univariate Cox and LASSO regression analyses to establish an M2‐TAM‐based prognostic signature.Results: CCL20, HLA‐DMA, HLA‐DRB5, KLF4, and TMSB4X were verified as prognostic M2‐like TAM‐related genes by univariate Cox and LASSO regression analyses. IPS and TMB analyses revealed that the high‐risk group responded better to common immunotherapy.Conclusion: The study shows the potential of the M2‐like TAM‐related gene signature in EGFR‐negative LUAD, explores the immune landscape based on M2‐like TAM‐related genes, and predict immunotherapy response of patients with EGFR‐negative LUAD, providing a new insight for individualized treatment.

28 March 2023 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
XDXiaoyang Duan
Xiaoyang Duan
HDHuazhen Du
Huazhen Du
RQRan Qi
Ran Qi
MYMeng Yuan
Meng Yuan
JSJian Shi
Jian Shi
Immunotherapy‑based regiments have potential as first‑line treatment for advanced gastric esophageal cancer. The present study aimed to conduct a meta‑analysis of the association between the efficacy and safety of first‑line immunotherapy combined with chemotherapy in patients with unresectable locally advanced or metastatic gastric esophageal cancer. Subgroup analysis of patients with programmed death ligand 1 (PD‑L1) combined positive score (CPS) was conducted to identify the characteristics of patients with immune benefit and to provide a decision‑making basis for clinical practice. PubMed, Embase, Cochrane Library and other databases were searched to collect randomized controlled trials of immunotreatment‑based regimens (experimental group) versus conventional first‑line chemotherapy regimens (control group) for unresectable locally advanced or metastatic gastric esophageal cancer. The main outcome measures included progression‑free survival (PFS), overall survival (OS), objective response rate, disease control rate and safety, and the secondary outcomes were the differences in OS and PFS between patients with PD‑L1 CPS ≥10 and those with PD‑L1 CPS <10. In addition, Asian and non‑Asian populations were analysed. Nine studies with a total of 6,820 patients were included. The OS of patients treated with immunotherapy‑based regimens was significantly longer than that of those treated with chemotherapy alone [HR=0.74; 95% CI (0.69, 0.80); P<0.00001]. The OS of patients with PD‑L1 CPS ≥10 and PD‑L1 CPS <10 in the experimental group was significantly longer than that of patients in the control group [HR=0.68; 95% CI (0.59, 0.77); P<0.00001 and HR=0.73; 95% CI (0.62, 0.87); P=0.0005]. The PFS of patients being treated with immunotherapy‑based regimens was significantly longer than that of those treated with chemotherapy alone [HR=0.71; 95% CI (0.59, 0.86); P=0.0003]. In addition, the PFS of patients with PD‑L1 CPS ≥10 and PD‑L1 CPS <10 in the experimental group was significantly longer than that of patients in the control group [HR=0.67; 95% CI (0.49, 0.92); P=0.01 and HR=0.63; 95% CI (0.48, 0.83); P=0.001]. There was no significant difference in the overall incidence of adverse events and the incidence of grade 3 or above adverse events between the experimental and control groups [RR=1; 95% CI (0.99, 1.02); P=0.65 and RR=0.97; 95% CI (0.84, 1.12); P=0.69, respectively]. In conclusion, treatment with immunotherapy‑based regimens may prolong the OS of patients with unresectable locally advanced or metastatic gastric esophageal cancer and this treatment regimen is safe compared with chemotherapy alone.